Evidence map›Paper›PMID 41590609›Full record

ArticleMetabolites2025

Metabolomics Plasma Biomarkers Associated with the HRD Phenotype in Ovarian Cancer.

Alessandro Tubita, Claudia De Angelis, Daniela Grasso, Flavia Sorbi, Francesca Castiglione, Lorenzo Anela, Maria Cristina Petrella, Massimiliano Fambrini, Federico Scolari, Andrea Bernini and 3 more

Abstract read
In one paragraph

Article in Metabolites, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alessandro TubitaDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0001-6977-5048
Claudia De AngelisOncology Unit, Careggi University Hospital, 50134 Florence, Italy.ORCID 0000-0003-0398-5610
Daniela GrassoDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.ORCID 0000-0001-7708-9339
Flavia SorbiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.ORCID 0000-0001-7277-6420
Francesca CastiglioneDepartment of Health Sciences, University of Florence, 50134 Florence, Italy.
Lorenzo AnelaDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0009-0001-8448-5951
Maria Cristina PetrellaOncology Unit, Careggi University Hospital, 50134 Florence, Italy.
Massimiliano FambriniDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Federico ScolariDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.ORCID 0000-0001-5490-672X
Andrea BerniniDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.ORCID 0000-0002-7528-2749
Giulia PetroniDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Serena PillozziDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.ORCID 0000-0001-8861-8718
Lorenzo AntonuzzoDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.

Funding

Ministero dell'università e della ricerca 58515_DIPECC_23_27
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biomarkerBRCA1/2 mutationshomologous recombination deficiency (HRD)liquid biopsyovarian cancer

Identifiers

PMID41590609
PMCPMC12843699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.